Stocktoria
Novartis AG NOVN.SW
Novartis AG (NOVN.SW) earns a Piotroski F-score of 8/9 (strong financial health). It pays a dividend yielding 3.24% (safety: moderate). FY2025 revenue was $56.7B at a 24.7% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 23 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
FAQ
Is NOVN.SW financially healthy?
Novartis AG's Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak).
Does NOVN.SW pay a dividend, and is it safe?
Yes. Novartis AG pays a dividend yielding about 3.24% with a 55.9% payout ratio, rated “moderate” for safety.
How profitable is NOVN.SW?
In FY2025, Novartis AG had a net margin of 24.7% and a return on equity of 30.3%.
Source: company filings via Yahoo Finance · CH · as of 2025-12-31. Figures in CHF; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.